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Abstract
Objective: Mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene are associated with pituitary 
adenoma, acromegaly and gigantism. Identical alleles in unrelated pedigrees could be inherited from a common 
ancestor or result from recurrent mutation events.
Design and methods: Observational, inferential and experimental study, including: AIP mutation testing; 
reconstruction of 14 AIP-region (8.3 Mbp) haplotypes; coalescent-based approximate Bayesian estimation of the time 
to most recent common ancestor (tMRCA) of the derived allele; forward population simulations to estimate current 
number of allele carriers; proposal of mutation mechanism; protein structure predictions; co-immunoprecipitation and 
cycloheximide chase experiments.
Results: Nine European-origin, unrelated c.805_825dup-positive pedigrees (four familial, five sporadic from the UK, 
USA and France) included 16 affected (nine gigantism/four acromegaly/two non-functioning pituitary adenoma 
patients and one prospectively diagnosed acromegaly patient) and nine unaffected carriers. All pedigrees shared 
a 2.79 Mbp haploblock around AIP with additional haploblocks privately shared between subsets of the pedigrees, 
indicating the existence of an evolutionarily recent common ancestor, the ‘English founder’, with an estimated 
median tMRCA of 47 generations (corresponding to 1175 years) with a confidence interval (9–113 generations, 
equivalent to 225–2825 years). The mutation occurred in a small tandem repeat region predisposed to slipped 
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strand mispairing. The resulting seven amino-acid duplication disrupts interaction with HSP90 and leads to a marked 
reduction in protein stability.
Conclusions: The c.805_825dup allele, originating from a common ancestor, associates with a severe clinical phenotype 
and a high frequency of gigantism. The mutation is likely to be the result of slipped strand mispairing and affects 
protein–protein interactions and AIP protein stability.
Introduction
Although the majority of pituitary adenomas are sporadic, 
they co-occur in families in about 2–5% of the cases 
(1). Rarely, they form a part of multi-glandular tumor 
syndromes, such as MEN1 or Carney complex. More 
frequently, these families present with isolated pituitary 
adenomas (familial isolated pituitary adenoma (FIPA) 
syndrome). A significant proportion (~20%) of these 
pedigrees carry one of a variety of heterozygous alleles in 
the aryl hydrocarbon receptor-interacting protein gene 
(AIP, MIM: 60555) (2, 3). AIP is a 330 amino-acid protein 
comprised of an N-terminal immunophilin-like domain 
(4) and a C-terminal domain with three tetratricopeptide 
(TPR) repeats (5) that are thought to be responsible for 
protein–protein interactions (1, 6). Disease-associated AIP 
alleles reported to date are mainly the result of nonsense, 
missense, deletion/insertion or splice site mutations, but 
a few large deletions and a promoter mutation have also 
been described (1, 7). AIP acts as a tumor suppressor gene, 
requiring a second somatic hit affecting the wild-type 
(WT) allele, with loss of heterozygosity identified in a 
number of cases (6, 8, 9).
Mutations leading to a truncated protein are dispersed 
over the entire gene, while missense mutations are more 
common in the C-terminal end of the molecule (6). 
Several alleles have been reported in different geographic 
regions and populations, raising the question whether 
they arose through recurrent mutation events (occurring 
at mutational hotspots in the gene) or are inherited from 
a recent common ancestor. The c.910C > T, p.R304* allele, 
for example, has been identified in several populations 
independently (Irish, Romanian, English, Italian, Indian, 
Mexican) (10, 11), consistent with this CpG locus being a 
mutational hotspot, but in two instances, it has also been 
shown to give rise locally to numerous patients originating 
from the same ancestor (Ireland and Italy) (10, 12).
We have previously reported the c.805_825dup, 
p.F269_H275dup AIP exon 6 in-frame duplication 
(rs267606578/EF643650) in three affected members 
of a family from the United Kingdom (3) and in an 
apparently sporadic giant from France (13). Here, we 
report seven additional pedigrees (four from the United 
Kingdom and three from the USA) with the same allele 
and provide evidence that they are all derived from a 
common ancestor. Using a coalescent-based approximate 
Bayesian computation approach, we estimate the time to 
most recent common ancestor (tMRCA), and by forward 
simulation, we estimate the current number of carriers. 
We hypothesize that slipped strand mispairing led to this 
unusual duplication and the inserted amino-acids render 
the protein extremely unstable and, at the same time, 
disrupt the binding site for crucial partner proteins.
Patients and methods
The study protocol was approved by the local ethics 
committees. All participants provided signed informed 
consent before the study. AIP genotyping (sequencing 
and multiplex ligation-dependent probe amplification) 
was performed as previously published (9, 14). We report 
nine c.805_825dup-positive pedigrees (Table  1, Fig.  1): 
two previously described, diagnosed in the United 
Kingdom (3) and France (13), and seven new ones, four 
diagnosed in the United Kingdom and three in the USA. 
All individuals have primarily European ancestry, with a 
known family link to the United Kingdom, but were not 
known to be related; they were living in France, different 
United Kingdom counties and two USA states (Maryland 
and Tennessee) (Fig. 1). Four of the nine pedigrees were 
FIPA families (Fig.  1), while five patients presented as 
simplex (apparently sporadic) cases.
We genotyped 14 short tandem repeat loci 
(microsatellites) around AIP (Fig. 2) in the index case of 
each pedigree, and in a second individual in each of the 
United Kingdom FIPA 1 and 2 pedigrees, as previously 
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described (10). Haplotypes were inferred using PHASE 
(15), incorporating phasing information from UK FIPA 
1 and 2 pedigrees. To obtain tMRCA estimates, we used 
a combined approach of coalescent theory calculations 
and simulation in an approximate Bayesian computation 
framework (16). We used ms (17) for the simulations, 
combining recombination and mutation rates in order 
to assess the probability of neither event in the region of 
interest, as previously described (11). Based on the tMRCA 
estimates, we employed a forward simulation approach 
(10, 11) to estimate the current number of carriers per 
generation. We reject simulations that generated <9 
carriers, because we observed in our dataset at least 9 
unrelated carriers.
A structural model for the mutated C-terminal 
domain of the AIP protein was generated by template-
based modeling, using the Phyre2 prediction server (18) 
(top templates PDB: 4aif and 4gcn; Phyre2 confidence 
score 100.0% and 99.6% respectively). Phyre2 uses the 
alignment of Hidden Markov models via HHsearch (19) 
to significantly improve the accuracy of alignment and 
detection rate. A match with a confidence score >90% 
indicates that the core of the protein is modeled at high 
accuracy (2–4 Å root mean square deviation from the 
native, true structure). However, surface loops can deviate 
from the native. Regions not covered by templates are 
modeled ab initio using the Poing algorithm embedded 
in Phyre2 (18).
The interaction between mutant AIP and HSP90, a well-
established AIP-interacting partner (5), was investigated 
by co-immunoprecipitation. The coding sequence of AIP 
with the c.805_825dup, p.F269_H275dup mutation (20) 
was sub-cloned into the pcDNA3.0 vector C-terminally 
to the Myc tag epitope (3). Myc-tagged p.F269_H275dup 
AIP and HA-tagged HSP90β were co-transfected in 
HEK293 cells (10 × 106, 20 µg of total plasmid DNA), using 
Lipofectamine 2000 (Life Technologies) following the 
manufacturer’s instructions. Cells were harvested 48 h later 
by trypsinization and resuspended in 1.5 mL of lysis buffer 
(150 mM NaCl, 10 mM Tris–HCl pH 7.5, 10% v/v glycerol, 
Table 1 Clinical features of the patients carrying the AIP c.805_825dup, p.F269_H275dup mutation.
 
 
No
 
 
Pedigree ID
Pituitary 
adenoma 
phenotype
No. of 
affected 
individuals
Affected individuals details (sex, 
age at onset/diagnosis – years, 
tumor size, diagnosis)
 
Treatment for 
pituitary disease
No. of 
unaffected 
carriers
Unaffected carriers 
details (gender, age 
at evaluation – years)
1 UK FIPA 1  
(3, 27)
GH 4 M, 11/15, Hyperplasia, 
Gigantism
TSS 5 F, 6; F, 6; F, 34; M, 
34; F, 58
    M, 15/26, Macro, Gigantism TSS, SSA, DA   
    M, 27.5/29, Macro, Acromegaly TCS   
    M, na/47, Micro, 
Acromegaly*,GIST
TSS   
2 UK FIPA 2 GH 2 M, 22/23, Macro, Gigantism TSS, XRT 2 F, 32; M, 71
    F, 24/28, nk, Acromegaly TSS   
3 US FIPA 1 GH/NFPA 2 F, 22/23, Macro, NFPA (silent 
GH pos)
TSS, XRT 1 F, na, 55  
(obligate carrier)
    M, 25/26, Macro, Acromegaly 
(apoplexy)
TSS 2x, XRT, SSA, 
pegvisomant
  
4 US FIPA 2 GH/NFPA 3 M, 17/17, Macro, Gigantism TSS 1 F, na, 60  
(obligate carrier)
    F, 12/13, Macro, Gigantism TCS + XRT   
    F, 34/40, Macro, NFPA 
(immunostaining not 
available)
TSS   
5 FranceSimplex 
(13)
GH 1 M, 9/14, Macro, Gigantism, 
psychosis
TSS+XRT+SSA+DA – –
6 UK Simplex 1 GH 1 M, 20/21, Macro, Gigantism TSS 2x, SSA, 
pegvisomant
– –
7 UK Simplex 2 GH 1 M, 13/18, Macro, Gigantism TSS, XRT – –
8 US Simplex GH 1 M, 17/17, Macro, Gigantism TSS, SSA, XRT, 
pegvisomant
– –
9 UK Simplex 3 GH 1 M, 18/23, Macro, Acromegaly TCS, XRT 1 F, 66
Definition of gigantism: abnormally high growth speed in children or teenagers with abnormal IGF-1 and GH during OGTT and/or height >3 s.d. above 
the mean height for age or >2 s.d. over the calculated midparental height.
*Asymptomatic patient prospectively diagnosed with acromegaly following genetic testing, TSS after 3 years of medical therapy. Also has GIST tumor 
under surveillance.
DA, dopaminergic therapy; GIST, gastrointestinal stromal tumor; na, not applicable; nk, not known; SSA, somatostatin analogue therapy, 
TCS, transcranial surgery; TSS, trans-sphenoidal surgery; XRT, radiation therapy.
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1% v/v IGEPAL CA-630 (Sigma-Aldrich) supplemented 
with Complete Protease Inhibitor Cocktail (Roche)). After 
being cleared by centrifugation, lysates were cleaned up by 
incubation with 50 µL of Protein G Sepharose 4 Fast Flow 
(GE Healthcare) and divided in thirds for incubation with 
5 µg of anti-Myc (Santa Cruz Biotechnology; clone 9E10) 
or anti-HA (Sigma-Aldrich H3663) mouse monoclonal 
antibodies, or mouse IgG (Sigma-Aldrich I5381), as 
appropriate. The co-immunoprecipitation was performed 
as previously described (21), and the eluates were resolved 
by denaturing polyacrylamide gel electrophoresis 
followed by Western blot using anti-Myc (Santa Cruz 
Biotechnology; clone 9E10) and anti-HA (Sigma-Aldrich 
H6908) antibodies. The experiment was repeated twice 
for confirmation.
Protein stability was assessed by cycloheximide 
chase experiments, as previously described (21). Briefly, 
Myc-tagged WT, p.F269_H275dup and p.R304* AIP 
Figure 2
Haplotype analysis of the nine AIP c.805_825dup pedigrees. Colored chromosomes carry the AIP mutation (purple stripe): dark 
shading indicates the conserved haploblock shared between all mutated chromosomes; light shading shows portions of the 
haplotype extending to the entire genotyped region in UK Simplex 1/USA FIPA 1 pedigrees; yellow/pink shading shows additional 
‘private’ sharing between closely related chromosomes. An allele mutation occurred at D11S1249 in patient US Simplex 2  
(red type font). The order of individuals is arbitrary to highlight the extended haplotype sharing between pedigrees. Pedigree 
codes correspond to Table 1. A full colour version of this figure is available at http://dx.doi.org/10.1530/EJE-17-0293.
Figure 1
Pedigrees of the FIPA families harboring 
the c.805_825dup, p.F269_H275dup AIP 
mutation and map of geographical 
locations of the AIP c.805_825dup 
pedigrees. Pedigree numbers correspond 
to the first column in Table 1. A full colour 
version of this figure is available at  
http://dx.doi.org/10.1530/EJE-17-0293.
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
177:3 261Clinical Study R Salvatori, S Radian, Y Diekmann, 
D Iacovazzo and others
Founder effect in AIP mutation
www.eje-online.org
were overexpressed in HEK293 cells, and the cells were 
subsequently treated with cycloheximide 20 μg/mL 
(Abcam) for the time indicated. Cell lysates were prepared 
for polyacrylamide gel electrophoresis and Western blot 
with anti-Myc (Santa Cruz Biotechnology; clone 9E10) 
and anti-GAPDH (Santa Cruz Biotechnology FL-335) 
antibodies. The normalized protein levels were expressed 
as percentage of those observed at time 0. The results of 
at least two independent experiments, in triplicates, were 
pooled together and analyzed using a one-phase decay 
equation. The degradation constant (K) was compared 
between the mutants and the WT protein using the 
extra sum-of-squares F test. Significance was set for 
P values <0.05.
Ethical approval
All procedures performed in studies involving human 
participants were in accordance with the ethical standards 
of the institutional and national research committee 
and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.
Results
The majority of the c.805_825dup-positive affected 
individuals presented with somatotropinoma (14 of 16 
patients), but two clinically non-functioning pituitary 
adenomas (NFPA) were also observed (Table  1). Two 
FIPA families were homogenous, with all affected 
members harboring somatotropinomas and the other 
two were heterogeneous with both somatotropinomas 
and clinically NFPAs (Fig. 1). From a total of 16 affected 
allele carriers (4F/12M), 13 patients (10M) presented 
with signs/symptoms of pituitary macroadenoma: eight 
gigantism (1F/7M), three acromegaly (3M), 2 clinically 
non-functioning pituitary adenomas (2F, one with 5–10% 
GH-positive cells while for the other immunostaining 
is not available) (Table  1). One asymptomatic male 
patient (UK FIPA 1), identified prospectively after 
genetic screening, had a GH-secreting pituitary 
microadenoma (IGF-1 = 1.5 × upper limit of normal) and 
a 1 cm gastrointestinal stromal tumor; after three years of 
medical therapy, his pituitary adenoma was successfully 
operated on, while he remains under surveillance for the 
gastrointestinal stromal tumor. One patient, originally 
operated at the age of 15 years when histology showed 
somatotroph hyperplasia, was suffering from diabetes 
and hypertension and died following leg surgery at the 
age of 35 years (UK FIPA 1). One subject (France Simplex) 
affected by gigantism had dilated cardiomyopathy, aortic 
dilatation and history of infantile psychosis.
The overall average age of onset of symptoms was 
19.1 years (median 18.5, range 9–34).
Haplotype analysis showed a 2.79–3.63 Mbp 
(1.83–2.59 cM) haploblock around AIP shared among 
c.805_825dup allele-carrying chromosomes in all nine 
pedigrees, as well as additional haploblocks shared among 
subsets of chromosomes, strongly supporting the existence 
of a recent common ancestor; the ‘English founder’ 
(Fig. 2). We observed a different allele of D11S1249 in one 
subject (US Simplex), on the c.805_825dup allele-carrying 
haplotype and conditioned our coalescent simulation 
results on the occurrence of a mutation at this locus.
We obtained tMRCA estimates of 47 (9–113) 
generations (median, 95% confidence interval (CI)), 
based on HapMap genetic distances (22) and 48 (13–101) 
generations, based on Rutgers map distances (Fig. 3A and 
B). Assuming a generation time of 25 years (23, 24), these 
estimates translate to 1175 (225–2825) years and 1200 
(325–2525) years respectively.
The estimated current number of carriers per 
generation – obtained through forward simulations – was 
32 (9–299) (median, 95% CI), based on HapMap genetic 
distances, and 32 (9–250), based on Rutgers map distances 
(Fig.  3C and D). These results integrate the uncertainty 
of the tMRCA estimates. Assuming that three 25-year 
generations co-exist at present, we estimate that 96 (27–
897) (median, 95% CI, HapMap-based) c.805_825dup 
carriers may exist today, of which only 25 have been 
identified so far.
We studied the structure of the DNA sequence around 
the 21 base-pair tandem duplication allele. We have 
identified a region in the normal sequence with two 
short repeated sequences separated by an intervening 
sequence (Fig. 4A and B), which is typical for a site prone 
to ‘replication slippage’. Tandem duplications associated 
with short direct repeats can be explained by the model 
of ‘replication slippage’ or ‘slipped strand mispairing’ 
(25, 26). The key feature of this model is that, during 
replication, the primer strand transiently dissociates 
from the template, slips backward or forward, and then 
re-associates at the short direct repeat resulting in a 
misaligned configuration (Fig.  4A). If the primer strand 
containing the newly synthesized second (i.e. 3′) repeat 
dissociates from the template strand and then misaligns 
at the first (i.e. 5′) direct repeat, continued DNA synthesis 
will lead to the insertion of one of two direct repeats 
plus the intervening sequence. In our case, the repeat 
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is imperfect (caaggcctac and caaggcccac) (Fig.  4B), the 
intervening sequence is ttcaagcgggg and the duplicated 
region is ttcaagcggggcaaggcccac.
The mutation results in the duplication of seven 
amino-acids in the third TPR domain of AIP (TPR3). 
These can adopt a helical conformation, thus adding a 1.9 
extra helical turn to the TPR3 alpha helix and increasing 
its length by 10.5 Å. The TPR3 domain is important for the 
interaction of AIP with other proteins, in particular, HSP90 
and TOMM7 peptides (5). Superposition between the WT 
C-terminal of the AIP molecule (PDB: 4AIF) and the mutant 
C-terminal AIP model shows that the seven amino acid 
duplication may displace K266, which is crucial for HSP90 
and possibly other partners binding (Fig.  4C, D and E), 
thus potentially leading to the disruption of AIP function. 
The results of a co-immunoprecipitation experiment 
with mutant AIP and HSP90 were consistent with lack of 
interaction between the two proteins (Fig. 5A), supporting 
the results of our in silico prediction. As compared with WT 
AIP, the steady state levels of the p.F269_H275dup protein 
were markedly reduced, and this led us to hypothesize 
an effect of the mutation on AIP protein stability as 
well, consistent with what has already been shown for 
several other AIP mutations (21). Cycloheximide chase 
experiments showed that the p.F269_H275dup mutation 
leads to a markedly unstable protein with a degradation 
constant K of 1.169, significantly higher than that of WT 
AIP (0.0593; P < 0.001) and even that of the truncating 
mutant p.R304* (0.3147; P < 0.05) (Fig.  5B), suggesting 
shorter protein half-life.
Discussion
AIP mutations are reported in about 20% of FIPA pedigrees 
(1, 27), but a higher percentage has been observed in 
homogenous acromegaly families. Over 90 AIP mutations 
have been described to date. The R304 locus seems to be 
the most prevalent mutational ‘hot spot’, with mutations 
affecting the c.C910 and c.G911 base-pairs of this CpG 
site, resulting in R304* and R304Q alleles reported in 
various countries and unrelated families (28). A few 
other mutations have also been described as recurring 
in diverse geographical regions, such as the p.R271W 
and the p.R81* (3, 29, 30, 31). In this paper, we report 
nine apparently unrelated pedigrees all carrying the same 
unique c.805_825dup, p.Phe269_His275dup AIP allele. 
Figure 3
Smoothed distribution of approximate 
Bayesian computation-simulated time to 
most recent common ancestor (tMRCA) 
estimates of the AIP c.805_825dup allele, 
unadjusted (blue curves) and adjusted 
(black curves) (11), based on HapMap (A) 
and Rutgers (B) genetic distances. Median, 
2.5th and 97.5th percentiles are given in 
the insert. Distribution of numbers of 
carriers obtained through forward 
simulations, calculated based on HapMap-
based (C) or Rutgers-based (D) time to 
most recent common ancestor (tMRCA) 
estimates randomly sampled from the 
adjusted distributions shown in A&B. 
Black bars show density histograms, red 
curves represent the smoothed 
distributions. Median, 2.5th and 97.5th 
percentiles are shown in the insert; the 
lower bound is conditioned to be nine 
carriers, the minimum observed number 
of carriers per generation in our cohort. 
A full colour version of this figure is 
available at http://dx.doi.org/10.1530/
EJE-17-0293.
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Seven of these pedigrees were not previously reported, 
and we provide updated information for the other two 
(3, 9, 13, 20).
When the same allele is identified in different 
families, the question arises whether this is the result of 
independent recurrent mutational events in a region of 
the genome that is more prone to mutations (‘hot spot’, 
such as CpG sites) (32) or the result of spreading of the 
disease-associated allele in the population originating 
from a single founder mutation event. The c.805_825dup, 
Figure 4
(A) Schematic drawing of the suggested replication slippage mechanism of the c.805_825dup, p.F269_H275dup AIP mutation. The 
purple and blue colorings match the sequences in (B). During DNA replication, the primer strand containing the newly 
synthesized second repeat transiently dissociates from the template, slips backward and then re-associates at the first short direct 
repeat of the template strand, resulting in a misaligned configuration. Continued DNA synthesis will lead to the insertion of 
intervening sequence and the second direct repeat, resulting in the mutated allele. (B) DNA sequences of WT AIP (bottom row) 
and of the mutated allele (top row), starting at the c.781 base-pair (NM_003977.2). Note the two 9 base-pair long repeats, the 5′ 
one marked in purple (caaggcctac) and the 3′ one marked in blue (caaggcccac). These are imperfect repeats as the 7th base-pair 
(in red font) is t in the 5′ repeat and c in the 3′ repeat. The intervening sequence between the two direct repeats is ttcaagcgggg. 
The underlined sequence is duplicated in the upper sequence, i.e. the mutated allele, in which the first copy of the duplicated 
sequence is underlined and the second copy of the duplicated sequence is italic. This duplication leads to three copies of the 9 bp 
repeat: the purple is the 5′ repeat, while the blue is the 3′ repeat which has been duplicated. (C, D and E) Cartoon representation 
of the AIP protein structure based on the crystal structure of the N and the C-terminal domains of the protein (4, 5). The first and 
second alpha helices of the WT AIP TPR2 and TPR3 motifs (C) are presented in light orange and dark orange respectively. Details 
of the wild-type (D) and mutant (E) AIP bound to the SRMEEVD peptide, a fragment of the HSP90 partner protein (shown in 
blue). The seven amino-acid duplication in the first helix of AIP TPR3 is shown in purple. Residue K266, which in the wild-type AIP 
interacts with the HSP90 peptide (or with TOMM20 peptide) (5) is displayed as a green stick. A full colour version of this figure is 
available at http://dx.doi.org/10.1530/EJE-17-0293.
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(p.Phe269_His275dup) involves the duplication of 21 
base-pairs and probably occurred via the ‘slipped strand 
mispairing’ mechanism (25, 26, 33) (Fig.  4A). Certain 
structural features of the genome can predispose a 
particular region to rearrangement, such as repeated 
sequences located relatively close to each other, raising 
the possibility that similar duplications might occur 
independently. On the other hand, while the patients 
described here reside in three different areas of the world, 
all the individuals have ancestral links to the United 
Kingdom. Furthermore, the steady flow of immigration 
from Britain to North America in recent centuries and 
the close proximity of England and France are consistent 
with an evolutionarily recent common ancestor. Indeed, 
the result of our haplotype analysis strongly indicates 
that all patients share a recent common ancestor, the 
‘English founder’, who lived approximately 1175  years 
ago. This estimate has, however, a wide 95% confidence 
interval of 225–2825 years. The cause of the geographic 
spreading of this allele is unknown, although mobility 
in the areas where carriers reside was historically high – 
particularly since the industrial revolution (34). The 
penetrance of the pituitary phenotype in patients with 
mutated AIP is known to be low (about 20%) (27). 
This is confirmed in the largest c.805_825dup-positive 
pedigree (UK FIPA 1), with an estimated penetrance of 
23% (assuming that 50% of the relatives not genotyped 
would be carriers). Because of this low penetrance, AIP 
mutations do not prevent reproduction in the majority 
of carriers. Furthermore, even patients who develop 
pituitary adenomas may maintain normal fertility until 
the adenoma is large enough to cause hypogonadism. 
Whether the mutated allele confers some kind of survival 
advantage is unknown (11).
It is important to note that four of the patients did 
not have a family history of pituitary adenoma. Following 
our haplotype analysis, these are unlikely to be de novo 
mutations. These patients were tested for AIP mutations 
because of their clinical characteristics (large adenomas 
developing at young age, with onset of symptoms ranging 
between 9 and 20 years), confirming previous reports of 
relatively high prevalence of AIP mutations in apparently 
sporadic GH-secreting macroadenomas of the youth 
(27, 35, 36).
The c.805_825dup AIP allele is pathogenic, as 
indicated by the clinical, in silico and experimental data. 
The mutation is predicted to affect AIP structure and 
function by altering a crucial interaction site between 
the third TPR domain of AIP (Fig.  4) and one of its 
most important partners, HSP90 (5), and this has been 
Figure 5
(A) The p.F269_H275dup AIP mutation disrupts the interaction 
with HSP90. Myc-tagged wild-type (WT) (left panel) or  
p.F269_H275dup (right panel) AIP were co-transfected with 
HA-tagged HSP90β in HEK293 cells. Co-immunoprecipitation 
was performed using anti-Myc or anti-HA mouse antibodies or 
mouse IgG. Eluates were resolved by denaturing polyacrylamide 
gel electrophoresis followed by Western blot using anti-Myc 
and anti-HA antibodies. Positive interaction was demonstrated 
between WT AIP and HSP90 (a band is also visible in the 
negative IgG control for HSP90 but not for AIP). No interaction 
was seen between p.F269_H275dup AIP and HSP90. The steady 
state levels of mutant AIP were reduced as compared with WT 
AIP (a band was visible in the Input only after increasing the 
contrast settings, figure not shown), suggesting that the 
mutation affects the stability of AIP as well (Fig. 5B). Top arrow: 
HA-HSP90, bottom arrow: Myc-AIP. Arrowheads: heavy (top) 
and light (bottom) chains of mouse immunoglobulins. MWM: 
molecular weight marker. IP: immunoprecipitation. 
(B) Cycloheximide chase experiment in HEK293 cells 
overexpressing Myc-tagged WT, p.R304* and p.F269_H275dup 
AIP. The transfected cells were incubated in the presence of 
cycloheximide 20 μg/mL for the time indicated. The left panel 
shows the degradation curves of each protein obtained after 
plotting the normalized protein levels as percentage of those 
observed at time 0. The right panel shows representative 
Western blot images. The degradation speed (K) of the p.F269_
H275dup mutant protein was significantly higher than that of 
WT AIP and that of the truncating mutant p.R304*. A full 
colour version of this figure is available at http://dx.doi.
org/10.1530/EJE-17-0293.
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confirmed experimentally (Fig. 5A). Mutations at protein–
protein binding sites are a common cause of disease as they 
can disrupt the interaction between molecules in cellular 
protein networks, which is required for correct protein 
function (37). An alternative pathogenic mechanism 
by which the c.805_825dup (p.F269_H275dup) affects 
AIP function is by causing the disruption of AIP protein 
folding, leading to increased proteasomal degradation, 
as we have previously shown for numerous AIP missense 
mutations (21). Here, we provided evidence that the 
p.F269_H275dup mutation markedly affects protein 
stability, leading to a protein that is significantly less stable 
compared with the common p.R304* truncating mutant.
In summary, we report the same AIP allele occurring in 
nine apparently unrelated pedigrees from three different 
(but linked through gene flow) countries and show that all 
the affected subjects, the majority suffering from young-
onset somatotropinomas, share a common ancestral 
haplotype. The mutation results in the duplication of 
seven amino-acids in third TPR domain of AIP, leading 
to the disruption of protein–protein interactions and 
markedly reduced protein stability.
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